{"id":"153sm-dotmp","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"5%","effect":"Vomiting"},{"rate":"8%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"153Sm-DOTMP is a radioligand that targets somatostatin receptors, which are overexpressed in certain types of tumors.","oneSentence":"A radioligand targeting somatostatin receptors","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T06:50:09.018Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"},{"name":"Neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT07197645","phase":"PHASE1","title":"Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2025-10-21","conditions":"Bone Pain, Metastatic Bone Tumor, Bone Metastases in Subjects With Advanced Cancer","enrollment":33},{"nctId":"NCT06008483","phase":"PHASE1","title":"A Dose Finding Study to Treat Bone Tumor(s)","status":"UNKNOWN","sponsor":"QSAM Therapeutics, Inc.","startDate":"2022-04-05","conditions":"Bone Cancer, Bone Tumor, Solid Tumor","enrollment":17},{"nctId":"NCT03612466","phase":"PHASE1","title":"A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy","status":"WITHDRAWN","sponsor":"Albert Einstein College of Medicine","startDate":"2022-08","conditions":"Osteosarcoma, Bone Metastases","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CycloSam"],"phase":"phase_1","status":"active","brandName":"153Sm-DOTMP","genericName":"153Sm-DOTMP","companyName":"Telix Pharmaceuticals (Innovations) Pty Limited","companyId":"telix-pharmaceuticals-innovations-pty-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A radioligand targeting somatostatin receptors Used for Prostate cancer, Neuroendocrine tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}